首頁 > 市場調查報告書 > 製藥

生物製劑

癌症生物療法市場規模、佔有率和成長分析（治療方法、癌症類型、給藥途徑、分銷管道和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1898563

癌症生物療法市場規模、佔有率和成長分析（治療方法、癌症類型、給藥途徑、分銷管道和地區分類）—2026-2033年產業預測

Cancer Biological Therapy Market Size, Share, and Growth Analysis, By Therapy Type (Monoclonal Antibodies, Cancer Vaccines), By Cancer Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球癌症生物療法市場規模將達到 1,085 億美元，到 2025 年將達到 1,164.2 億美元，到 2033 年將達到 2045.6 億美元，預測期（2026-2033 年）的複合年成長率為 7.3%。

由於癌症發病率不斷上升以及專業治療機構的激增，全球生物癌症療法市場預計將顯著擴張。專家正利用奈米技術開發先進的治療方案，為個人化癌症治療創造可能。對生物療法的關注以及奈米技術的融合有望變革癌症治療，使每位患者都能獲得更個人化和有效的治療效果。隨著該領域持續的研發和技術進步，生物癌症療法市場預計將迎來顯著成長，從而加強對抗癌症的鬥爭，並有助於改善全球整體。

全球癌症生物製劑治療市場促進因素

全球癌症發生率的不斷上升是推動全球癌症生物製劑市場擴張的主要動力。尤其值得注意的是，小細胞肺癌（SCLC）病例的增加，這種癌症主要影響60至80歲的人，已成為一項緊迫的醫療挑戰。 SCLC的高死亡率以及肺癌作為癌症相關死亡的主要原因，進一步凸顯了創新治療方法的緊迫性。這些因素推動了對癌症生物製劑的需求，相關人員正在尋求有效的解決方案來應對和克服日益嚴重的全球癌症負擔，從而推動了市場的發展。

限制全球癌症生物療法市場的因素

癌症治療方法帶來的高昂經濟負擔嚴重阻礙了全球癌症生物療法市場的擴張。這些治療方法費用高昂，尤其對於經濟低度開發地區和農村地區的患者而言，限制了他們獲得可能挽救生命的治療的機會。這項經濟挑戰極大地限制了市場的覆蓋範圍，迫使許多患者因經濟拮据而選擇療效較差或替代治療方法。因此，整個市場發展面臨挑戰，難以為更廣泛的患者群體提供必要的治療。

全球生物癌症治療市場趨勢

在全球基因組學和分子生物學進步的推動下，癌症生物療法市場正經歷著向個人化和標靶治療的顯著轉變。隨著人們對腫瘤獨特的遺傳和分子特徵了解的不斷深入，針對特定基因異常和生物標記的生物療法的研發日益重要。這種個人化治療能夠改善患者預後，最大限度地減少副作用，並提高療效。透過針對腫瘤生長和發展過程中涉及的潛在分子機制，這些創新治療方法正在革新癌症治療，實現對各種癌症類型的更精準、更有效的管理，從而重塑腫瘤治療格局。

單株抗體
- 裸單株抗體
- 偶聯單株抗體
- 雙特異性單株抗體
癌症疫苗
- 預防性疫苗
- 治療性疫苗
細胞激素療法
- 白細胞介素
- 干擾素
過繼性細胞移植
- CAR-T細胞療法
- 腫瘤浸潤淋巴細胞
- TCR療法
免疫查核點抑制劑
- PD-1/PD-L1抑制劑
- CTLA-4抑制劑
標靶癌症生長抑制劑
- 蛋白酪氨酸激酶抑制劑（TKIs）
- 蛋白酶體抑制劑（PIs）
- mTOR抑制劑
血液細胞生長因子（BCGF）
- 來諾格拉司亭
- Filgrastim
- 其他 BCGF
溶瘤病毒療法
基因治療
其他治療方法

全球癌症生物療法市場規模（按癌症類型分類）（2019-2032 年）

肺癌
乳癌
大腸直腸癌
攝護腺癌
白血病
胰臟癌
卵巢癌
其他癌症類型

全球癌症生物療法市場按給藥途徑分類（2019-2032 年）

靜脈注射
皮下注射
瘤內給藥
口服
其他

全球癌症生物療法市場規模（按分銷管道分類）（2019-2032 年）

網路藥房
零售藥房
醫院藥房

全球癌症生物療法市場規模（2019-2032 年）

北美（治療方法、癌症類型、給藥途徑、通路分類）
- 美國
- 加拿大
歐洲（治療方法、癌症類型、給藥途徑、通路分類）
- 英國
- 德國
- 西班牙
- 法國
- 義大利
- 其他歐洲地區
亞太地區（依治療方法、癌症類型、給藥途徑、分銷管道分類）
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲（依治療方法、癌症類型、給藥途徑、分銷管道分類）
- 巴西
- 墨西哥
- 其他拉丁美洲地區
中東和非洲（按治療方法、癌症類型、給藥途徑、分銷管道分類）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭對手儀錶板

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）

主要企業簡介

Pfizer Inc.
The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
Merck & Co.
Bristol Myers Squibb
F. Hoffmann-La Roche Ltd
Novartis AG
AstraZeneca
Amgen Inc.
Eli Lilly and Company
Sanofi
AbbVie Inc.
GlaxoSmithKline Plc.
Bayer AG
Exelixis Inc.
Incyte
BioNTech SE
Adaptimmune
Nanobiotix
Vir Biotechnology Inc.
Innate Pharma Inc.
AdcentrX Therapeutics

結論和分析師建議

簡介目錄

Product Code: SQMIG35H2207

Global Cancer Biological Therapy Market size was valued at USD 108.5 Billion in 2024 and is poised to grow from USD 116.42 Billion in 2025 to USD 204.56 Billion by 2033, growing at a CAGR of 7.3% during the forecast period (2026-2033).

The global market for cancer biological therapy is set to expand significantly, driven by the increasing incidence of cancer and the proliferation of specialized treatment facilities. Experts are innovating with nanotechnology to develop advanced therapeutic solutions, creating opportunities for personalized cancer care. The emphasis on biological therapies and the integration of nanotechnology present transformative potential for cancer treatment, allowing for more tailored and effective patient outcomes. As research and technological advancements continue to progress in this field, the market for cancer biological therapy is poised for remarkable growth, enhancing efforts in the ongoing battle against cancer and improving the overall landscape of cancer care globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biological Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biological Therapy Market Segments Analysis

Global Cancer Biological Therapy Market is segmented by Therapy Type, Cancer Type, Route of Administration, Distribution Channel and region. Based on Therapy Type, the market is segmented into Monoclonal Antibodies, Cancer Vaccines, Cytokine Therapy, Adoptive Cell Transfer, Immune Checkpoint Inhibitors, Targeted Cancer Growth Blockers, Blood Cell Growth Factors (BCGF), Oncolytic Virus Therapy, Gene Therapy and Other Therapy Types. Based on Cancer Type, the market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Pancreatic Cancer, Ovarian Cancer and Other Cancer Types. Based on Route of Administration, the market is segmented into Intravenous (IV), Subcutaneous, Intratumoral, Oral and Others. Based on Distribution Channel, the market is segmented into Online Pharmacies, Retail Pharmacies and Hospital Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biological Therapy Market

The escalating incidence of cancer across the globe significantly propels the expansion of the global cancer biological therapy market. The rise in cases, particularly of Small Cell Lung Cancer (SCLC), predominantly affects individuals in their sixties to eighties, highlighting a pressing healthcare challenge. The substantial mortality associated with SCLC and the prevalence of lung cancer as a leading cause of cancer-related deaths further underline the urgent need for innovative treatment options. These factors create a heightened demand for cancer biological therapies, as stakeholders seek effective solutions to manage and combat the growing cancer burden worldwide, thereby driving the market's progress.

Restraints in the Global Cancer Biological Therapy Market

The high financial burden linked to cancer treatment methods creates a notable obstacle for the expansion of the Global Cancer Biological Therapy market. The elevated costs of these therapies can be prohibitive, particularly for individuals in economically disadvantaged or rural regions, limiting their access to potentially life-saving treatments. This affordability issue significantly restricts the market's reach, as numerous patients may opt for less effective or alternative remedies due to financial constraints. Consequently, this challenges the overall development of the market and hampers its ability to provide necessary therapies to a broader population in need.

Market Trends of the Global Cancer Biological Therapy Market

The global cancer biological therapy market is experiencing a significant trend towards personalized and targeted treatment modalities, driven by advancements in genomics and molecular biology. As the unique genetic and molecular characteristics of tumors become increasingly well-documented, the development of biological therapies tailored to address specific genetic abnormalities and biomarkers has gained prominence. This customization leads to improved patient outcomes, minimized side effects, and enhanced therapeutic efficacy. By concentrating on the underlying molecular mechanisms responsible for tumor growth and proliferation, these innovative therapies are revolutionizing cancer treatment, enabling more precise and effective management of various cancer types, thereby reshaping the therapeutic landscape in oncology.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impact Factor
Top Investment Pockets
Market Attractiveness Index
Market Ecosystem
PESTEL Analysis
Regulatory Landscape
Case Study Analysis
Value Chain Analysis
Patent Analysis
Technology Analysis
Clinical Trial Analysis
Disease Epidemiology

Global Cancer Biological Therapy Market Size by Therapy Type (2019-2032)

Market Overview
Monoclonal Antibodies
- Naked MAB
- Conjugated MAB
- Bispecific MAB
Cancer Vaccines
- Preventive Vaccines
- Therapeutic Vaccines
Cytokine Therapy
- Interleukins
- Interferons
Adoptive Cell Transfer
- CAR T-cell therapy
- Tumor-Infiltrating Lymphocytes
- TCR therapy
Immune Checkpoint Inhibitors
- PD-1/PD-L1 inhibitors
- CTLA-4 inhibitors
Targeted Cancer Growth Blockers
- Tyrosine Kinase Inhibitors (TKIs)
- Proteasome Inhibitors (PIs)
- mTOR Inhibitors
Blood Cell Growth Factors (BCGF)
- Lenograstim
- Filgrastim
- Other BCGF
Oncolytic Virus Therapy
Gene Therapy
Other Therapy Types

Global Cancer Biological Therapy Market Size by Cancer Type (2019-2032)

Market Overview
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Leukemia
Pancreatic Cancer
Ovarian Cancer
Other Cancer Types

Global Cancer Biological Therapy Market Size by Route of Administration (2019-2032)

Market Overview
Intravenous (IV)
Subcutaneous
Intratumoral
Oral
Others

Global Cancer Biological Therapy Market Size by Distribution Channel (2019-2032)

Market Overview
Online Pharmacies
Retail Pharmacies
Hospital Pharmacies

Global Cancer Biological Therapy Market Size (2019-2032)

North America (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
- US
- Canada
Europe (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Dashboard

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025

Key Company Profiles

Pfizer Inc.
- Company Overview
- Product Portfolio Overview
- Financial Overview
- Key Developments
The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
Merck & Co.
Bristol Myers Squibb
F. Hoffmann-La Roche Ltd
Novartis AG
AstraZeneca
Amgen Inc.
Eli Lilly and Company
Sanofi
AbbVie Inc.
GlaxoSmithKline Plc.
Bayer AG
Exelixis Inc.
Incyte
BioNTech SE
Adaptimmune
Nanobiotix
Vir Biotechnology Inc.
Innate Pharma Inc.
AdcentrX Therapeutics